These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 3056251)

  • 1. Association between early inhibition of DNA synthesis and the MICs and MBCs of carboxyquinolone antimicrobial agents for wild-type and mutant [gyrA nfxB(ompF) acrA] Escherichia coli K-12.
    Chow RT; Dougherty TJ; Fraimow HS; Bellin EY; Miller MH
    Antimicrob Agents Chemother; 1988 Aug; 32(8):1113-8. PubMed ID: 3056251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
    Cohen SP; McMurry LM; Hooper DC; Wolfson JS; Levy SB
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1318-25. PubMed ID: 2679373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic characterization of quinolone-resistant mutants of Enterobacteriaceae selected from wild type, gyrA type and multiply-resistant (marA) type strains.
    Piddock LJ; Hall MC; Walters RN
    J Antimicrob Chemother; 1991 Aug; 28(2):185-98. PubMed ID: 1663926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a rapid assay for detecting gyrA mutations in Escherichia coli and determination of incidence of gyrA mutations in clinical strains isolated from patients with complicated urinary tract infections.
    Ozeki S; Deguchi T; Yasuda M; Nakano M; Kawamura T; Nishino Y; Kawada Y
    J Clin Microbiol; 1997 Sep; 35(9):2315-9. PubMed ID: 9276409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro selection of fluoroquinolone-resistant Neisseria gonorrhoeae harboring alterations in DNA gyrase and topoisomerase IV.
    Yasuda M; Fukuda H; Yokoi S; Ishihara S; Kawada Y; Deguchi T
    J Urol; 2000 Sep; 164(3 Pt 1):847-51. PubMed ID: 10953166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.
    Hooper DC; Wolfson JS; Souza KS; Ng EY; McHugh GL; Swartz MN
    Antimicrob Agents Chemother; 1989 Mar; 33(3):283-90. PubMed ID: 2658782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
    Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
    Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of gyrA and gyrB mutations in quinolone-resistant clinical isolates of Escherichia coli by single-strand conformational polymorphism analysis and determination of levels of resistance conferred by two different single gyrA mutations.
    Ouabdesselam S; Hooper DC; Tankovic J; Soussy CJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1667-70. PubMed ID: 7486897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa.
    Jalal S; Wretlind B
    Microb Drug Resist; 1998; 4(4):257-61. PubMed ID: 9988043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between the expression of ompF and quinolone resistance in Escherichia coli.
    Kishii R; Takei M
    J Infect Chemother; 2009 Dec; 15(6):361-6. PubMed ID: 20012725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Resistance to quinolones and beta-lactams in Salmonella enterica due to mutations in topoisomerase-encoding genes, altered cell permeability and expression of an active efflux system].
    Miró E; Vergés C; García I; Mirelis B; Navarro F; Coll P; Prats G; Martínez-Martínez L
    Enferm Infecc Microbiol Clin; 2004 Apr; 22(4):204-11. PubMed ID: 15056435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinolone action in Escherichia coli cells carrying gyrA and gyrB mutations.
    Herrera G; Aleixandra V; Urios A; Blanco M
    FEMS Microbiol Lett; 1993 Jan; 106(2):187-91. PubMed ID: 8384139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of action of and resistance to ciprofloxacin.
    Hooper DC; Wolfson JS; Ng EY; Swartz MN
    Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates.
    Morgan-Linnell SK; Becnel Boyd L; Steffen D; Zechiedrich L
    Antimicrob Agents Chemother; 2009 Jan; 53(1):235-41. PubMed ID: 18838592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel gyrA point mutation in a strain of Escherichia coli resistant to fluoroquinolones but not to nalidixic acid.
    Cambau E; Bordon F; Collatz E; Gutmann L
    Antimicrob Agents Chemother; 1993 Jun; 37(6):1247-52. PubMed ID: 8392306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of in vitro susceptibilities to newer quinolones of naturally occurring quinolone-resistant Neisseria gonorrhoeae strains with changes in GyrA and ParC.
    Shultz TR; Tapsall JW; White PA
    Antimicrob Agents Chemother; 2001 Mar; 45(3):734-8. PubMed ID: 11181352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.